<DOC>
	<DOCNO>NCT01422915</DOCNO>
	<brief_summary>The investigator demonstrate cholestyramine effective binding agent vitro porphyrin . A isolated case report treatment individual cutaneous porphyria suggest cholestyramine colestipol effectively remove porphyrin . Hypothesis : orally administer colestipol effectively low erythrocyte porphyrin concentration subject erythropoietic protoporphyria ( EPP ) .</brief_summary>
	<brief_title>Sorbent Therapy Cutaneous Porphyrias</brief_title>
	<detailed_description>Four adult proven EPP volunteer subject study . Initial phase ( pre-Rx ) : CBC ; liver chemistry include cholesterol ; serum iron , TIBC ferritin ; erythrocyte plasma protoporphyrin concentration ; completion questionnaire focus cutaneous manifestation complete week 2 4 . Treatment Phase 1 : colestipol tablet , 1 gram morning 1 gram bedtime 3 month , repetition test end month 2 3 . Treatment Phase 2 : colestipol tablet , 2 gram morning 2 gram bedtime 3 month , repetition test end month 2 3 . Post-Treatment - repetition test end month 1 , 2 3 .</detailed_description>
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria , Erythropoietic</mesh_term>
	<mesh_term>Protoporphyria , Erythropoietic</mesh_term>
	<mesh_term>Colestipol</mesh_term>
	<criteria>Adult age 21 healthy Intercurrent illness pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Sorbent</keyword>
	<keyword>Resin</keyword>
	<keyword>EPP</keyword>
	<keyword>Cutaneous porphyria</keyword>
	<keyword>Adult</keyword>
	<keyword>age 21</keyword>
	<keyword>without intercurrent illness</keyword>
	<keyword>pregnant</keyword>
	<keyword>willing participate</keyword>
</DOC>